Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

This is the logo of the provider
Denver, Colorado ,  USA 5 - 9 November 2026

American Association for the Study of Liver Diseases (AASLD 2026)

Teaser video
Medical Commentary: Liver Health, MASLD and MASH
In this interview, Dr. Eric Lawitz discusses liver health, MASLD and MASH, including identifying people at risk, fibrosis risk stratification and the use of non-invasive tests. He also shares his perspective on integrating liver health into cardiometabolic care and improving the evaluation and management of people with MASH.

The views and opinions expressed in this video are those of Dr. Eric Lawitz and do not necessarily reflect the official position of Novo
Presentation schedule and materials
Friday, 06 November 2026
13:00  - 14:00
MST
POSTER
Real-world comparative effectiveness of semaglutide versus resmetirom on liver enzymes and cardiometabolic markers in patients with MASH
Prachi Arora1; David Shi1; Abdalla Aly1; Husam Albarmawi1; Maximilian Kurt Jara1; Eric Lawitz2
MATERIALS AVAILABLE
2461-arora-prachi-1
Poster
13:00  - 14:00
MST
POSTER
Semaglutide 2.4 mg and the Changes in Liver Enzymes and Cardiometabolic Markers in Patients with MASH: A Retrospective Cohort Study
Husam Albarmawi1; David Shi1; Abdalla Aly1; Katie Brown2; Katie Gilbert2; Sunny Guin2; Ben Hong2; Maximilian Kurt Jara1; Amy Wu2; Eric Lawitz3, 4
MATERIALS AVAILABLE
2473-albarmawi-husam-1
Poster
13:00  - 14:00
MST
POSTER
The Economic Burden of Patients with Metabolic Dysfunction Associated Steatohepatitis Stratified by Baseline and Changes in FIB-4 Index
David Shi1; Abdalla Aly1; Andres Quintero1; Guanghao Zhang1; Husam Albarmawi1; Hashem B. El-Serag2
MATERIALS AVAILABLE
2631-shi-david-1
Poster
13:00  - 14:00
MST
POSTER
The Impact of Cardiometabolic Risk Factors on Health Care Resource Use in Adult Patients Living with Steatotic Liver Disease
Guanghao Zhang1; Abdalla Aly1; Andres Quintero1; David Shi1; Aidan McGovern1; Hashem B. El-Serag2
MATERIALS AVAILABLE
2163-shi-david-1
Poster
13:00  - 14:00
MST
POSTER
ACT on MASH – US Data: A survey of awareness, understanding, and perceptions of MASLD and MASH among healthcare professionals
Husam Albarmawi1*; Nathalie Eklöf2*;Maximilian Jara1; Jeff McIntyre3; Marco Antonio Petti1; Lauren D. Nephew4
MATERIALS AVAILABLE
6-2526-albarmawi-husam
Poster
13:00  - 14:00
MST
POSTER
ACT on MASH – US Data: A survey of awareness, understanding, and perceptions of MASLD and MASH among people living with MASLD/MASH or at risk for MASH
Husam Albarmawi1*; Nathalie Eklöf2*;Maximilian Jara1; Jeff McIntyre3; Marco Antonio Petti1; Lauren D. Nephew4
MATERIALS AVAILABLE
7-2556-albarmawi-husam
Poster
Saturday, 07 November 2026
13:00  - 14:00
MST
POSTER
Efruxifermin improved fibrosis in participants with MASH cirrhosis and multiple cardiometabolic comorbidities: a post hoc analysis of the SYMMETRY Phase 2b trial
Mary Rinella1; Alex Liberman2; Sonja Billes2; Meena Jain2; Mazen Noureddin3
MATERIALS AVAILABLE
aasld2026-3548-rinella
Poster
13:00  - 14:00
MST
3544
POSTER
Multi-omic dissection of the direct mechanism of action of efruxifermin-mediated reversal of lipotoxicity in primary human hepatocytes​
Suyavaran Arumugam1; Michail Kokkorakis1; Tim Rolph2; Erik Tillman2; Wajahat Mehal1,3
MATERIALS AVAILABLE
3544-kokkorakis-michail-1
Poster
13:00  - 14:00
MST
3360
POSTER
The FGF21 analog EFX regulates intercellular fibrogenic signaling by disrupting hepatocyte to stellate cell transfer of dysfunctional mitochondria​
Suyavaran Arumugam1; Xinshou Ouyang1; Tim Rolph2; Erik Tillman2; Wajahat Mehal1,3
MATERIALS AVAILABLE
3360-arumugam-suyavaran-mito-transfer-1
Poster
Sunday, 08 November 2026
11:00  - 11:15
MST
:0087
POSTER
Effects of zalfermin, cagrilintide, and semaglutide on non-invasive fibrosis biomarkers in alcohol-related liver disease: ​A phase 2 randomized trial
Vijay Shah1; Juan Pablo Arab2; Ramon Bataller3; Jerome Boursier4; Jacob George5; Lise Lotte Gluud6; Kenichi Ikejima7; Maria Rodrigo-Domingo8; Mazen Noureddin9,10; ​Jörn M. Schattenberg11,12; Ahsan Shoeb8,13; Irina Yoffe8; Aleksander Krag14
MATERIALS AVAILABLE
shah-effects-of-zalfermin-cagrilintide-and-semaglutide-on-non-invasive-fibrosis-biomarkers-in-alcohol-related-liver-disease
Slide
0087-shah-vijay
Poster
11:45  - 12:00
MST
:0072
POSTER
Semaglutide improves liver health in non‑obese participants with MASH: A post hoc analysis from the phase 3 ESSENCE trial
Jörn M. Schattenberg1; Matthew J. Armstrong2; Igor Bakulin3; Anja Geerts4; Jacob George5; Ewa Janczewska6; Niels Krarup7; Chun-Jen Liu8; Håvard Midgard9; Ahsan Shoeb7; Thea Vestergaard7; Michael Roden on behalf of the ESSENCE Study Group​10
MATERIALS AVAILABLE
schattenberg-semaglutide-improves-liver-health-in-non‑obese-participants-with-mash
Slide
0072-schattenberg-jorn-poster
Poster
12:45  - 13:30
MST
Symposium
FGF21 analogs in focus: From pathways to clinical evidence in MASH
Arun Sanyal ;  Kris Kowdley
MATERIALS AVAILABLE
aasld-2026-tlm-infographic-v3_0
Infographic
fgf21-analogs-in-focus-teaser-video
Teaser Video
14:30  - 14:45
MST
0066
ORAL PRESENTATION
Efruxifermin drives multidimensional histologic improvement in compensated cirrhosis: An AI-based analysis from the SYMMETRY randomized controlled trial​
Mazen Noureddin1; Jӧrn Schattenberg2; Vlad Ratziu3; Ylaine Gerardin4; Alyson R. Warr4; Jacqueline Brosnan-Cashman4; Doreen Chan5; Erik J. Tillman5; Reshma Shringarpure5; Mary E. Rinella6
MATERIALS AVAILABLE
akero-pathai-symmetry-aasld-final
Slide
Keywords
MASH
NASH
AASLD